PolyNovo share price jumps 10% following $2 million December month

PolyNovo’s stock was first put into a voluntary trading halt before revealing an impressive set of NovoSorb BTM sales figures from the December (CY19) month.

It’s been a positively busy period for Polynovo shareholders.

As we wrote just recently in December:

‘News that Polynovo’s (ASX: PNV) NovoSorb BTM had been granted a certificate of conformance – sent the share price of the now $1.28bn tech-focused healthcare company up as much as 27%.'

This was a significant development for the fast-growing company, as it ‘will give PolyNovo the green light to sell its NovoSorb BTM product throughout the UK, Ireland and the European Union,’ we previously wrote.

PolyNovo share price: more bullish news

Building on those bullish developments, today PolyNovo provided the market with an update regarding its December and H1 FY20 sales performance.

Here, and on an unaudited basis, PolyNovo revealed that revenue from the company's cornerstone NovoSorb BTM product – for the December month (CY19) had reached $2m – representing a 134% increase from the December prior.

This was a first for the company.

Looking at the broad top-line growth in the 2020 fiscal year, the company further reported that H1 FY20 revenue came in at $8.57m – a significant increase from H1 FY19's revenue of $3.75m.

PolyNovo now boasts a market capitalisation of $1.2bn.

Speaking of sales 'ramping' up in recent times, PolyNovo's Chief Executive Officer, Paul Brennan said:

'We are pleased with the sales trend. However, as a word of caution sales will continue to be lumpy as new sales staff are added and new territories opened up and because of natural disasters such as fires and volcanoes.’

Other comments – focusing on the company’s expansionist plans also likely caught investor attention today, with Mr Brennan further noting:

‘The expansion of the US sales team is adding to the sales momentum and we expect to see further acceleration of sales as a result of increased in-territory sales and the wider territory coverage coming from new staff hires. We are appointing more salespeople in the US to drive revenue and we are still actively recruiting.'

In response to this news of PolyNovo’s ‘two million dollar month,’ the company’s share price rose 10.74% – to $2.01 per share – by 16:04 AEDT.

Other news: more developments still to come

The company reported that a full set of audited financial results will be released on February 26.

Polynovo (ASX: PNV) also commented that it would soon release additional information on the current EU/UK prospects following the company's recently received certificate of conformance. PolyNovo’s Chairman – David Williams – expects sales to accelerate as a consequence of this approval.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.